The Oncology Institute of Hope & Innovation Launches Oregon Market
The Oncology Institute (TOI), a leading value-based oncology group, has expanded into Oregon with the opening of two new specialty cancer clinics in Portland and Salem. This marks TOI's first capitated partnership in the market, with plans for further expansion across the state. The new clinics will offer cutting-edge cancer care services, providing a vital option for patients in the Pacific Northwest.
Dr. Dan Virnich, CEO of TOI, emphasized the company's commitment to providing advanced care in local communities, focusing on optimal outcomes, patient satisfaction, and minimizing financial burdens. Dr. Patan Gultawatvichai, Medical Director of TOI in Oregon, highlighted the company's dedication to redefining oncology care through value-based models.
TOI, founded in 2007, serves over 1.8 million patients across more than 70 clinic locations with over 120 employed clinicians and 700 team members. The company offers advanced services including clinical trials and transfusions, aiming to change oncology for the better.
L'Istituto di Oncologia (TOI), un importante gruppo oncologico basato sul valore, ha espanso la sua attività in Oregon con l'apertura di due nuove cliniche oncologiche specializzate a Portland e Salem. Questo segna il primo partenariato capitato di TOI nel mercato, con piani per ulteriori espansioni in tutto lo stato. Le nuove cliniche offriranno servizi di assistenza oncologica all'avanguardia, fornendo un'opzione fondamentale per i pazienti del Pacifico Nordovest.
Il Dott. Dan Virnich, CEO di TOI, ha enfatizzato l'impegno dell'azienda a fornire cure avanzate nelle comunità locali, concentrandosi su risultati ottimali, soddisfazione dei pazienti e minimizzazione dei costi finanziari. Il Dott. Patan Gultawatvichai, Direttore Medico di TOI in Oregon, ha sottolineato la dedizione dell'azienda a ridefinire l'assistenza oncologica attraverso modelli basati sul valore.
TOI, fondata nel 2007, serve oltre 1,8 milioni di pazienti in più di 70 sedi cliniche con oltre 120 clinici impiegati e 700 membri del team. L'azienda offre servizi avanzati tra cui sperimentazioni cliniche e trasfusioni, puntando a migliorare l'oncologia.
El Instituto de Oncología (TOI), un grupo líder de oncología basado en el valor, se ha expandido a Oregón con la apertura de dos nuevas clínicas de cáncer especializadas en Portland y Salem. Esto marca la primera asociación capitada de TOI en el mercado, con planes para una expansión adicional en todo el estado. Las nuevas clínicas ofrecerán servicios de atención integral contra el cáncer, proporcionando una opción vital para los pacientes en el Noroeste del Pacífico.
El Dr. Dan Virnich, CEO de TOI, enfatizó el compromiso de la empresa de brindar atención avanzada en las comunidades locales, centrándose en los mejores resultados, la satisfacción del paciente y la minimización de las cargas financieras. El Dr. Patan Gultawatvichai, Director Médico de TOI en Oregón, destacó la dedicación de la empresa a redefinir la atención oncológica a través de modelos basados en el valor.
TOI, fundada en 2007, atiende a más de 1.8 millones de pacientes en más de 70 ubicaciones clínicas con más de 120 clínicos empleados y 700 miembros del equipo. La empresa ofrece servicios avanzados que incluyen ensayos clínicos y transfusiones, con el objetivo de mejorar la oncología.
종양학 연구소(TOI)는 가치 기반의 선도적인 종양학 그룹으로서, 오리건으로 확장하며 포틀랜드와 세일럼에 두 개의 새로운 전문 암 클리닉을 열었습니다. 이는 TOI의 첫 번째 자본 파트너십으로, 주 전역에 추가 확장을 계획하고 있습니다. 새로운 클리닉은 최첨단 암 치료 서비스를 제공하여 태평양 북서부의 환자들에게 중요한 선택지를 제공할 것입니다.
TOI의 CEO인 Dan Virnich 박사는 지역 사회에 향상된 치료를 제공하겠다는 회사의 의지를 강조하며, 최적의 결과, 환자 만족 및 재정적 부담 최소화에 집중한다고 언급했습니다. 오리건의 TOI 의료 책임자인 Patan Gultawatvichai 박사는 가치 기반 모델을 통해 종양학 치료를 재정의하려는 회사의 헌신을 강조했습니다.
2007년에 설립된 TOI는 180만 명 이상의 환자를 70개 이상의 클리닉 위치에서 치료하며 120명 이상의 고용된 의사와 700명의 팀원이 있습니다. 이 회사는 임상 시험 및 수혈을 포함한 고급 서비스를 제공하며, 종양학을 더욱 개선하는 것을 목표로 하고 있습니다.
L'Institut d'Oncologie (TOI), un groupe onkologique de premier plan basé sur la valeur, s'est étendu dans l'Oregon avec l'ouverture de deux nouvelles cliniques spécialisées dans le cancer à Portland et Salem. Cela marque le premier partenariat capitée de TOI sur le marché, avec des plans d'expansion supplémentaires dans tout l'État. Les nouvelles cliniques offriront des services de soins contre le cancer à la pointe de la technologie, fournissant une option essentielle pour les patients du Nord-Ouest Pacifique.
Dr. Dan Virnich, CEO de TOI, a souligné l'engagement de l'entreprise à fournir des soins avancés dans les communautés locales, en se concentrant sur des résultats optimaux, la satisfaction des patients et la minimisation des charges financières. Dr. Patan Gultawatvichai, Directeur Médical de TOI dans l'Oregon, a mis en avant la volonté de l'entreprise de redéfinir les soins en oncologie grâce à des modèles basés sur la valeur.
Fondé en 2007, TOI sert plus de 1,8 million de patients dans plus de 70 sites cliniques avec plus de 120 cliniciens employés et 700 membres du personnel. L'entreprise offre des services avancés, y compris des essais cliniques et des transfusions, avec l'objectif d'améliorer l'oncologie.
Das Oncology Institute (TOI), eine führende wertorientierte Onkologiegemeinschaft, hat sich in Oregon erweitert und zwei neue spezialisierte Krebsambulanzen in Portland und Salem eröffnet. Dies markiert TOIs erste kapitale Partnerschaft auf dem Markt mit Plänen für eine weitere Expansion im ganzen Bundesstaat. Die neuen Kliniken werden modernste Krebsbehandlungsangebote bereitstellen und eine wichtige Option für Patienten im pazifischen Nordwesten bieten.
Dr. Dan Virnich, CEO von TOI, betonte das Engagement des Unternehmens, fortschrittliche Pflege in lokalen Gemeinschaften anzubieten, indem es sich auf optimale Ergebnisse, Patientenzufriedenheit und Minimierung finanzieller Belastungen konzentriert. Dr. Patan Gultawatvichai, Medizinischer Direktor von TOI in Oregon, hob das Engagement des Unternehmens hervor, die Onkologieversorgung durch wertbasierte Modelle neu zu definieren.
TOI, gegründet im Jahr 2007, betreut über 1,8 Millionen Patienten an über 70 Klinikstandorten mit mehr als 120 angestellten Kliniker und 700 Teammitgliedern. Das Unternehmen bietet fortschrittliche Dienstleistungen wie klinische Studien und Transfusionen an und strebt an, die Onkologie zum Besseren zu verändern.
- Expansion into Oregon market with two new specialty cancer clinics
- First capitated partnership in the Oregon market
- Plans for further expansion in Oregon as additional partnerships develop
- Offering cutting-edge cancer care services in the Pacific Northwest
- Serving over 1.8 million patients across more than 70 clinic locations
- None.
Insights
The expansion of The Oncology Institute (TOI) into Oregon marks a significant strategic move, potentially impacting the company's growth trajectory and market presence. This expansion, anchored by a value-based payor partnership, aligns with the industry trend towards cost-effective, patient-centric care models.
Key points to consider:
- Market Expansion: Entry into Oregon represents geographical diversification, potentially increasing TOI's patient base and revenue streams.
- Value-Based Care: The capitated partnership model in Oregon reinforces TOI's commitment to value-based oncology care, which could lead to improved cost management and patient outcomes.
- Competitive Advantage: Offering advanced cancer care services in community settings may differentiate TOI from traditional hospital-based oncology services.
- Growth Potential: Plans for further expansion within Oregon suggest a long-term growth strategy in the Pacific Northwest region.
While this expansion is promising, investors should monitor the execution of this strategy, including patient acquisition rates, operational efficiency in the new market and the financial impact of the capitated model on TOI's bottom line.
TOI's expansion into Oregon represents a significant development in the competitive landscape of oncology care. The company's value-based model, focusing on community-based care, addresses several critical issues in cancer treatment:
- Accessibility: By bringing advanced cancer care to community settings, TOI is improving patient access to cutting-edge treatments.
- Cost Management: The capitated partnership model aims to reduce the financial burden on patients and payors, a important factor in the current healthcare economy.
- Clinical Trials: Offering clinical trials in community settings could accelerate patient enrollment and diversify trial populations.
The expansion aligns with broader industry trends towards decentralized, value-based care models in oncology. However, success will depend on TOI's ability to maintain quality care while managing costs effectively under the capitated model. Investors should watch for metrics on patient outcomes, cost savings and the scalability of this model in new markets.
Anchor value-based payor partnership leads to opening of locations in Portland and Salem
CERRITOS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the nation, is proud to announce its expansion into Oregon with the opening of two new specialty cancer clinics. The clinic locations in Portland and Salem will mark TOI’s first capitated partnership in the market, with plans to expand to other markets in the state as additional partnerships develop. Both initial Oregon clinic locations will offer cutting edge cancer care services, offering a vital new option for patients in the Pacific Northwest.
“At TOI, we believe that every cancer patient deserves access to the most advanced care in their community,” said Dr. Dan Virnich, Chief Executive Officer of TOI. “We’re excited to bring a new cancer care option to Oregon residents that prioritizes optimal outcomes, patient satisfaction, and minimizing the financial burden often linked to cancer treatment, aligning with our mission and the needs of the community.”
Dr. Patan Gultawatvichai, Medical Director of TOI in Oregon, added, “TOI is redefining oncology care through our commitment to value-based care. I’m thrilled to lead and grow this model in Oregon. We are delighted to welcome the community and look forward to expanding our team with professionals who are dedicated to advancing the future of cancer care.”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
FAQ
What new locations has The Oncology Institute (TOI) opened in Oregon?
What type of partnership has TOI established in Oregon?
Who is the Medical Director of TOI in Oregon?
How many patients does TOI serve and how many clinic locations does it have?
What is TOI's stock symbol?
